Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04936009 · ClinicalTrials.gov registry record · NA

Transcranial Magnetic Stimulation (TMS) Study for Adults With Autism Spectrum Disorder (ASD)

A NA study of Autism Spectrum Disorder, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT04936009 is a NA study of Autism Spectrum Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 60 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04936009, a NA study of Autism Spectrum Disorder, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This is a randomized interventional study designed to evaluate the effects of repetitive Transcranial Magnetic Stimulation (rTMS) on neural and behavioral facets of social cognition in adults with autism spectrum disorder (ASD).

Conditions Studied

Interventions

  • BEHAVIORAL Transcranial Magnetic Stimulation (TMS)

Study Locations (1)

Connecticut

  • Yale University Child Study Center - New Haven

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-03-17
Est. Completion 2027-07-01
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT04936009

The ClinicalTrials.gov registry entry for NCT04936009 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (56% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which Transcranial Magnetic Stimulation (TMS) is the first listed.

NCT04936009 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT04936009 about?

NCT04936009 is a clinical study titled "Transcranial Magnetic Stimulation (TMS) Study for Adults With Autism Spectrum Disorder (ASD)". This is a randomized interventional study designed to evaluate the effects of repetitive Transcranial Magnetic Stimulation (rTMS) on neural and behavioral facets of social cognition in adults with autism spectrum disorder (ASD).

What is the current status of trial NCT04936009?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2022-03-17. Estimated completion is 2027-07-01.

What conditions does trial NCT04936009 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder.

What interventions are being tested in trial NCT04936009?

The interventions under investigation include: Transcranial Magnetic Stimulation (TMS) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04936009?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04936009 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.